Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Deficient Mismatch Repair”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT02359565
What this trial is testing

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeLynch SyndromeMalignant Glioma+8 more
National Cancer Institute (NCI) 71
Large-scale testing (Phase 3)Ended earlyNCT06321068
What this trial is testing

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Who this might be right for
Endometrial Cancer
Bio-Thera Solutions 5
Not applicableLooking for participantsNCT06708429
What this trial is testing

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Who this might be right for
Lynch SyndromeLynch Syndrome ILynch Syndrome II+19 more
San Raffaele University 300
Testing effectiveness (Phase 2)Study completedNCT04439214
What this trial is testing

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 47
Not applicableUnknownNCT04774367
What this trial is testing

Evaluation of the Reliability of the Determination of MisMatch Repair Deficiency Status by Endoscopic Biopsies in Oesophagus and Gastric Adenocarcinoma.

Who this might be right for
Gastro-oesophageal Adenocarcinoma
Assistance Publique - Hôpitaux de Paris 300
Testing effectiveness (Phase 2)UnknownNCT04521075
What this trial is testing

A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

Who this might be right for
Melanoma Stage IVUnresectable MelanomaNSCLC Stage IV
Ella Therapeutics Ltd 42
Not applicableStudy completedNCT05257057
What this trial is testing

Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome

Who this might be right for
Lynch SyndromeEndometrial CancerEndometrial Hyperplasia+2 more
WellSpan Health 91
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06646445
What this trial is testing

Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

Who this might be right for
Colon Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group 60
Testing effectiveness (Phase 2)Study completedNCT06428487
What this trial is testing

Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Who this might be right for
Colorectal Cancer
Blokhin's Russian Cancer Research Center 30
Testing effectiveness (Phase 2)Study completedNCT05116085
What this trial is testing

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Who this might be right for
Colorectal Cancer
BeiGene 33
Testing effectiveness (Phase 2)Looking for participantsNCT06362369
What this trial is testing

Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Who this might be right for
Advanced CancerAdvanced Solid TumorMelanoma+15 more
7 Hills Pharma, LLC 126
Testing effectiveness (Phase 2)Study completedNCT02060188
What this trial is testing

Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Who this might be right for
Microsatellite Unstable Colorectal CancerMicrosatellite Stable Colorectal CancerMismatch Repair Proficient Colorectal Cancer+1 more
Bristol-Myers Squibb 385
Early research (Phase 1)Study completedNCT02635672
What this trial is testing

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Vincerx Pharma, Inc. 110
Early research (Phase 1)Looking for participantsNCT07208136
What this trial is testing

JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Jemincare 102
Not applicableActive Not RecruitingNCT00261456
What this trial is testing

The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer

Who this might be right for
Prostate CancerBRCA MutationMismatch Repair Gene Mutation+1 more
Institute of Cancer Research, United Kingdom 3,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05231850
What this trial is testing

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

Who this might be right for
Colon Cancer
The First Affiliated Hospital of Zhengzhou University 70
Not applicableUnknownNCT05728814
What this trial is testing

DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer

Who this might be right for
Endometrial Cancer
Grupo Español de Investigación en Cáncer de Ovario 100
Testing effectiveness (Phase 2)WithdrawnNCT06400264
What this trial is testing

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT05913570
What this trial is testing

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer

Who this might be right for
Colorectal CancerMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)+1 more
LiuYing 22
Testing effectiveness (Phase 2)Looking for participantsNCT07140679
What this trial is testing

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Who this might be right for
Localized Colon CarcinomaStage IIB Colon Cancer AJCC v8Stage IIC Colon Cancer AJCC v8+1 more
Emory University 40
Next Page